Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.
Madhav V. Dhodapkar, MBBS, the Anise McDaniel Brock Chair and Georgia Research Alliance Eminent Scholar in Cancer Innovation, leader of the cancer immunology research program at Winship Cancer Institute, director of the Winship Center for Cancer Immunology and professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses some of the immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecifics, currently under investigation for the treatment of patients with multiple myeloma.
At the 20th International Myeloma Society Annual Meeting, Dhodapkar highlighted linvoseltamab (REGN5458), a BCMA/CD3 bispecific being investigated in the phase 2 LINKER-MM1 study (NCT03761108). Here he advises community oncologists on what they should know about the safety and efficacy of the agent moving forward.
Transcription:
0:10 | Community oncologists are looking for options for [patients with] myeloma who have received multiple lines of therapy, and this really provides 1 of those options. It has a safety profile that we believe will eventually allow the usage of this in the community because it is in the end going to be the community oncologist who is going to be involved in administering this drug. Improving their familiarity with the adverse event of this therapy is going to be important over time. Obviously, the initial studies are often done in academic settings, but the drug will eventually be given, we believe, by the community doctors themselves.
1:02 | We're all very excited about the several immune-based therapies that have remarkable promise, this being 1 of them. There are other immune-based therapies, both CAR T’s and bispecifics, that are showing remarkable efficacy in different stages of myeloma. They are being tested in earlier stages of disease. I believe that even with this class of drugs, this specific drug will eventually move in that setting. I think that's really what we're excited about. It is a new change in sort of how we approach management of therapies, less chemotherapy, and sort of less conflict.
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More